Article
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
The Journal of clinical investigation - 1 Nov 2008
Cragg Mark S, Jansen Elisa S, Cook Michele, Harris Claire, Strasser Andreas, Scott Clare L
Abstract excerpt
B-RAF is frequently mutated in solid tumors, resulting in activation of the MEK/ERK signaling pathway and ultimately tumor cell growth and survival. MEK inhibition in these cells results in cell cycle arrest and cytostasis. Here, we have shown that MEK inhibition also triggers limited apoptosis of human tumor cell lines with B-RAF mutations and that this effect was dependent on upregulation and dephosphorylation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.